Hemp-Derived Cannabidiol (CBD) Wellness Products & Distribution
Strategic Profile
cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions. In January 2026, cbdMD acquired substantially all assets of Bluebird Botanicals, a long-standing CBD brand. The company believes that increased regulatory clarity will favor well-capitalized, compliance-focused operators with strong quality and safety standards.
Cyborg Score Rationale
cbdMD has a market cap of approximately 9.7M, indicating a micro-cap stock. The company remained unprofitable, posting an operating loss near $286,000 and slightly negative adjusted EBITDA. While the Bluebird Botanicals acquisition and regulatory science platform represent positive strategic moves, execution risk and capital constraints present significant challenges.
Top Insights
cbdMD completed its January 2026 Bluebird Botanicals acquisition, which adds an established revenue base, branded consumer loyalty, and patented-process technologies, with management expecting cost and revenue synergies.
The combined regulatory science assets create one of the most comprehensive safety and regulatory dossiers spanning both broad-spectrum and full-spectrum cannabinoid formulations.
The U.S. THC beverage market grew to $1.6 billion in 2025 with projected growth to $3.5 billion by 2030, supporting cbdMD's Herbal Oasis brand expansion.
Net loss shrank to $0.32M in Q1 FY2026 as cbdMD lifted cash to $3.4M and closed its Bluebird Botanicals deal.
Named Competitors
CBD Tinctures & Topicals — Large-cap CBD competitor with established brands